| Immunomodulation & island-cell transplantation: Diabetes cured in 7 years? |
| | Diabetes mellitus is a beta-cell disease |
|
| | Immunomodulation - diabetes cured in 7 years? |
|
| Prevention |
| | Prevention |
|
| Rationale for late intervention: preservation of residual beta-cell function |
| | Sustainded beta-cell function is associated with a reduced rate of new-onset albuminuria or worsening of retinopathy |
|
| Potential late interventions for preservation of beta-cell mass |
|
|
|
|
|
|
| Targeting islet inflammation in de novo type 1 diabetes for β-cell preservation |
| | Prevention |
|
| Islet transplantation - diabetes cured in 7 years? |
| | Curing diabetes! Pancreas transplantation |
|
| Regression of coronary atherosclerosis after pancreas transplantation |
| | Benefit of SPK over LDK transplantation in recipients with type 1 diabetes |
|
| Islet transplantation – since 2007 in the Netherlands (LUMC) (5-10/year) |
| | Islet isolation procedure |
|
| | Transplantation outcome |
|
| Clinical benefit: chronic diabetic complications |
| | Clinical benefit in islet-after kidney: improved kidney graft survival |
|
| Current options for beta-cell therapy in the LUMC |
| | Shortage of organ donors NL 256 (2011) |
|
| Evidence for islet neogenesis from the duct epithelium in human adults |
| | Isolation of human duct cells after islet isolation |
|
| Intact ducti develop “organoids” in matrigel |
| | In vivo differentiation: organoid transplantation under the kidney capsule |
|
| Organoids under the kidney capsule differentiate to insulin producing cells |
|
Deel deze pagina met collega's en vrienden: